Ventricular Tachycardia Risk with Long-Term Cilostazol Use

Mechanism of V-Tach Risk with Cilostazol

• Cilostazol is a phosphodiesterase III (PDE III) inhibitor that increases intracellular cyclic AMP, which is the mechanism believed to account for both its vasodilatory effects and its potential to trigger ventricular tachycardia 1, 2

Documented Side Effects Related to Arrhythmias

• Palpitations and tachycardia are among the common side effects reported with cilostazol use 2, 4

Contraindications and Monitoring

• Cilostazol is absolutely contraindicated in patients with heart failure of any severity due to the increased risk of ventricular tachycardia 1, 2, 4, 5
• The American College of Cardiology/American Heart Association guidelines emphasize that cilostazol should not be administered to patients with congestive heart failure of any severity 4

Clinical Implications and Recommendations

• For patients requiring long-term cilostazol therapy, evaluate tolerance at 2-4 weeks after initiation and assess clinical benefit within 3-6 months 4, 5
• Approximately 20% of patients discontinue cilostazol within the first 3 months due to side effects, including cardiovascular effects 2, 5